Head-to-head evidence
Adipose-derived MSC clusters (S.Biomedics) vs BGC101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: No discrete molecular target · full Atherosclerotic Cardiovascular Disease pipeline
Adipose-derived MSC clusters (S.Biomedics)
Developed by S.Biomedics
NCT04661644 · Phase 1/2 · completed
The study was nonrandomized, open-label, and had no placebo or standard-treatment control arm; it enrolled 20 participants across sequential dose groups. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
BGC101
Developed by BioGenCell
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Adipose-derived MSC clusters (S.Biomedics)'s landscape · BGC101's landscape